Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and its ligand (PD-L1), and inhibitors of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The introduction of immunoth...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Xinyu Wu, Yi Fung Chau, Hua Bai, Xiaofei Zhuang, Jie Wang, Jianchun Duan
स्वरूप:	लेख
भाषा:	English
प्रकाशित:	Frontiers Media S.A. 2023-01-01
श्रृंखला:	Frontiers in Oncology
विषय:	non-small cell lung cancer neoadjuvant therapy immune checkpoint inhibitors PD-L1 circulating tumor DNA tumor mutation burden
ऑनलाइन पहुंच:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1099304/full

समान संसाधन

Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach
द्वारा: Alessia Zotta, और अन्य
प्रकाशित: (2024-10-01)

Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy
द्वारा: Yu Wang, और अन्य
प्रकाशित: (2024-06-01)

Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study
द्वारा: Kevin R. Shieh, और अन्य
प्रकाशित: (2021-08-01)

Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
द्वारा: Shixiang Wang, और अन्य
प्रकाशित: (2019-09-01)

POLE/POLD1 mutation and tumor immunotherapy
द्वारा: Xiaoting Ma, और अन्य
प्रकाशित: (2022-07-01)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
द्वारा: Rilan Bai, और अन्य
प्रकाशित: (2020-08-01)

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
द्वारा: Xiaobin Zheng, और अन्य
प्रकाशित: (2023-07-01)

Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
द्वारा: Shixiang Wang, और अन्य
प्रकाशित: (2019-11-01)

Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
द्वारा: Lavinia Gatteschi, और अन्य
प्रकाशित: (2021-10-01)

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
द्वारा: Elizabeth M. Burton, और अन्य
प्रकाशित: (2022-06-01)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
द्वारा: Huiru Dai, और अन्य
प्रकाशित: (2022-08-01)

Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer
द्वारा: Huanlan SA, और अन्य
प्रकाशित: (2019-06-01)

Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
द्वारा: Sarah Perdikis-Prati, और अन्य
प्रकाशित: (2023-06-01)

The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis
द्वारा: Jinlong Cao, और अन्य
प्रकाशित: (2022-06-01)

Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis
द्वारा: Jie Zhao, और अन्य
प्रकाशित: (2022-03-01)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
द्वारा: Wei Nie, और अन्य
प्रकाशित: (2022-05-01)

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
द्वारा: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, और अन्य
प्रकाशित: (2021-11-01)

Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
द्वारा: Zhu Zeng, और अन्य
प्रकाशित: (2021-03-01)

Review of Immunogenomics and the Role of Tumor Mutational Burden as a Biomarker for Immunotherapy Response
द्वारा: Javier Ros, और अन्य
प्रकाशित: (2019-10-01)

Subclonal landscape of cancer drives resistance to immune therapy
द्वारा: Daniel J. Craig, और अन्य
प्रकाशित: (2022-01-01)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
द्वारा: Qing Li, और अन्य
प्रकाशित: (2022-12-01)

What is the status of immunotherapy in thyroid neoplasms?
द्वारा: Alejandro Garcia-Alvarez, और अन्य
प्रकाशित: (2022-08-01)

Biomarkers for non-small cell lung cancer immunotherapy
द्वारा: D. A. Kharagezov, और अन्य
प्रकाशित: (2021-09-01)

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
द्वारा: Jan Budczies, और अन्य
प्रकाशित: (2018-12-01)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
द्वारा: Yu Chen, और अन्य
प्रकाशित: (2020-09-01)

The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer
द्वारा: Fajiu Li, और अन्य
प्रकाशित: (2022-06-01)

Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis
द्वारा: Xiaoyan Qian, और अन्य
प्रकाशित: (2023-03-01)

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
द्वारा: Nai-Wen Kang, और अन्य
प्रकाशित: (2021-11-01)

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
द्वारा: Kai Ma, और अन्य
प्रकाशित: (2022-11-01)

Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
द्वारा: Chang QI, और अन्य
प्रकाशित: (2024-02-01)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
द्वारा: Jie Zhu, और अन्य
प्रकाशित: (2022-12-01)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
द्वारा: Alessandra Raimondi, और अन्य
प्रकाशित: (2020-08-01)

Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
द्वारा: Rui-Yan Wu, और अन्य
प्रकाशित: (2023-01-01)

Complete Response to Immunotherapy Combined With Chemotherapy in a Patient With Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma With High Tumor Mutational Burden: A Case Report
द्वारा: Xingyun Su, और अन्य
प्रकाशित: (2022-06-01)

Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis
द्वारा: Yuqian Feng, और अन्य
प्रकाशित: (2024-01-01)

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis
द्वारा: Zhen Yuan, और अन्य
प्रकाशित: (2023-01-01)

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
द्वारा: Xu Yang, और अन्य
प्रकाशित: (2024-01-01)

A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma
द्वारा: Qian Wang, और अन्य
प्रकाशित: (2023-01-01)

Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy
द्वारा: Annie Borch, और अन्य
प्रकाशित: (2023-03-01)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
द्वारा: Hongling Liang, और अन्य
प्रकाशित: (2021-12-01)